A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
Completed · Phase 1 · Has a placebo group
Conditions studied: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
In brief
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic parameters of VX-407 in healthy participants.
Key facts
- Study ID
- NCT06345755
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 159
- Starts
- 2024-04-17
- Expected to finish
- 2025-06-13
- Last updated by the study team
- 2025-07-14
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- ICON Lenexa — Lenexa, Kansas, United States
- Altasciences Montreal — Montreal, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.